Similar articles for PMID: 25086042

Year	Number of Results
1998	1
2002	1
2004	1
2006	2
2008	1
2009	2
2010	5
2011	7
2012	12
2013	16
2014	24
2015	11
2016	13
2017	15
2018	9
2019	12
2020	14
2021	32
2022	30
2023	13
2024	1

1

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hessein M, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Dalal K, et al. J Biol Chem. 2014 Sep 19;289(38):26417-26429. doi: 10.1074/jbc.M114.553818. Epub 2014 Aug 1. J Biol Chem. 2014. PMID: 25086042 Free PMC article.

2

Selectively targeting the dimerization interface of human androgen receptor with small-molecules to treat castration-resistant prostate cancer.

Dalal K, Ban F, Li H, Morin H, Roshan-Moniri M, Tam KJ, Shepherd A, Sharma A, Peacock J, Carlson ML, LeBlanc E, Perez C, Duong F, Ong CJ, Rennie PS, Cherkasov A. Dalal K, et al. Cancer Lett. 2018 Nov 28;437:35-43. doi: 10.1016/j.canlet.2018.08.016. Epub 2018 Aug 27. Cancer Lett. 2018. PMID: 30165195

3

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201).

Borgmann H, Lallous N, Ozistanbullu D, Beraldi E, Paul N, Dalal K, Fazli L, Haferkamp A, Lejeune P, Cherkasov A, Gleave ME. Borgmann H, et al. Eur Urol. 2018 Jan;73(1):4-8. doi: 10.1016/j.eururo.2017.08.012. Epub 2017 Aug 26. Eur Urol. 2018. PMID: 28851578

4

Discovery of small-molecule inhibitors selectively targeting the DNA-binding domain of the human androgen receptor.

Li H, Ban F, Dalal K, Leblanc E, Frewin K, Ma D, Adomat H, Rennie PS, Cherkasov A. Li H, et al. J Med Chem. 2014 Aug 14;57(15):6458-67. doi: 10.1021/jm500802j. Epub 2014 Aug 4. J Med Chem. 2014. PMID: 25062331

5

Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.

Hirayama Y, Tam T, Jian K, Andersen RJ, Sadar MD. Hirayama Y, et al. Mol Oncol. 2020 Oct;14(10):2455-2470. doi: 10.1002/1878-0261.12770. Epub 2020 Aug 9. Mol Oncol. 2020. PMID: 32734688 Free PMC article.

6

An androgen receptor N-terminal domain antagonist for treating prostate cancer.

Myung JK, Banuelos CA, Fernandez JG, Mawji NR, Wang J, Tien AH, Yang YC, Tavakoli I, Haile S, Watt K, McEwan IJ, Plymate S, Andersen RJ, Sadar MD. Myung JK, et al. J Clin Invest. 2013 Jul;123(7):2948-60. doi: 10.1172/JCI66398. Epub 2013 Jun 3. J Clin Invest. 2013. PMID: 23722902 Free PMC article.

7

Targeting Androgen Receptor Activation Function-1 with EPI to Overcome Resistance Mechanisms in Castration-Resistant Prostate Cancer.

Yang YC, Banuelos CA, Mawji NR, Wang J, Kato M, Haile S, McEwan IJ, Plymate S, Sadar MD. Yang YC, et al. Clin Cancer Res. 2016 Sep 1;22(17):4466-77. doi: 10.1158/1078-0432.CCR-15-2901. Epub 2016 May 2. Clin Cancer Res. 2016. PMID: 27140928 Free PMC article.

8

Sintokamide A Is a Novel Antagonist of Androgen Receptor That Uniquely Binds Activation Function-1 in Its Amino-terminal Domain.

Banuelos CA, Tavakoli I, Tien AH, Caley DP, Mawji NR, Li Z, Wang J, Yang YC, Imamura Y, Yan L, Wen JG, Andersen RJ, Sadar MD. Banuelos CA, et al. J Biol Chem. 2016 Oct 14;291(42):22231-22243. doi: 10.1074/jbc.M116.734475. Epub 2016 Aug 30. J Biol Chem. 2016. PMID: 27576691 Free PMC article.

9

Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation.

Lallous N, Leblanc E, Munuganti RS, Hassona MD, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns ES, Rennie PS, Cherkasov A. Lallous N, et al. Mol Cancer Ther. 2016 Dec;15(12):2936-2945. doi: 10.1158/1535-7163.MCT-16-0354. Epub 2016 Oct 7. Mol Cancer Ther. 2016. PMID: 27765852 Free PMC article.

10

Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells.

Nakka M, Agoulnik IU, Weigel NL. Nakka M, et al. Int J Biochem Cell Biol. 2013 Apr;45(4):763-72. doi: 10.1016/j.biocel.2012.12.012. Epub 2012 Dec 25. Int J Biochem Cell Biol. 2013. PMID: 23270728 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

191 results

Results by year